» Solide Tumore und Neoplasien » Verschiedene solide Tumore/Neoplasien
Alle Linien
ARROS-1 (NVL-520-01) Phase-1/2-Studie zu NVL-520 bei Patienten mit fortgeschrittenem NSCLC und anderen soliden Tumoren (Aktiv)
BI 907828 This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors) (Aktiv)
BO41932 - TAPISTRY Tumordiagnostische Präzisionsimmunoonkologie und somatisches Targeting rational rational for you (TAPISTRY) Phase II - Plattformversuch (Aktiv)
BrigaPed A Phase I/II study of Brigatinib in pediatric and young adult patients with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or other solid tumors (Aktiv)
CMCS110Z2102 A Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies (Aktiv)
CONKO-011 Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients (Aktiv)
CodeBreak 101 A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (Aktiv)
IMbrella B An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) (Aktiv)
LIBERAL Liberal transfusion strategy to prevent mortality and anaemia-associated, ischaemic events in elderly non-cardiac surgical patients (Aktiv)
MAESTRO Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases (Aktiv)
MK-3475-587 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (Aktiv)
MR Linac Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac (Aktiv)
NEPO_MUC Neoadjuvante Strahlentherapie (N-RT) zur Behandlung von intrazerebalen Metastasen solider Tumore (Aktiv)
NOA-26 - IT-PD1 Intrathekale Anwendung von PD1-Antikörpern bei metastasierten soliden Tumoren mit leptomeningealer Erkrankung (Aktiv)
ROSETTA RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial (ROSETTA) (Aktiv)
SIP (CHAI) Simultane integrierte Protektion zur Schonung der kritischen Organe in der Nähe von Läsionen bei der Körperstereotaxie (Aktiv)
SPIN-MET, SPIME2013 Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost (SPIN-MET) (Aktiv)
SenPET Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (Aktiv)
Erstlinie
Abbvie M23-385 A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. (Aktiv)
Keynote-158, MK3475-158 Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (Aktiv)
LCNEC-ALPINE A Phase II, single-arm trial of addition of Atezolizumab to standard chemotherapy of Platinum and Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung (Aktiv)
TAS-120-206 A Phase 2 Study of Futibatinib in Combination with PD-1 Antibody-based Standard of Care Therapy in Patients with Solid Tumors (TAS-120-206) (Aktiv)
Zweitlinie oder später
AMG305_20220073 Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (Aktiv)
ANV600-001 EXPAND-1 A first-in-human, open-label, multicenter Phase I/II study to evaluate the safety and anti-tumor activity of ANV600 as single agent and in combination with pembrolizumab in participants with relapsed/refractory advanced solid tumors (Aktiv)
Amgen 20210023 Eine Phase-1/1b/2-Studie zur Bewertung der Sicherheit, Verträglichkeit, Pharmakokinetik, Pharmakodynamik und Wirksamkeit von AMG 193 allein und in Kombination mit Docetaxel bei Patienten mit fortgeschrittenen soliden MTAP-null-Tumoren (Aktiv)
BMS CA052-002 A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors (Aktiv)
BNT211-01 A Trial to Evaluate the Safety and Efficacy of CLDN6 CAR-T +/- CLDN6 RNA-LPX (Aktiv)
BoB Module 1 A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (Aktiv)
CA030-001 An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Aktiv)
CHORDOM (HIT-1 / CH.P.12C) Trial of Proton Versus Carbon Ion Radiation Therapy in Patients With Chordoma of the Skull Base (HIT-1) (Aktiv)
CHRO761A12101 Eine offene, multizentrische Phase-I/Ib-Dosisfindungs- und Expansionsstudie von HRO761 als Einzelwirkstoff und in Kombinationen bei Patienten mit fortgeschrittenen soliden Tumoren mit hoher Mikrosatelliteninstabilität oder Mismatch-Reparaturmangel Studie von HRO761 allein oder in Kombination bei Krebspatienten mit spezifischen DNA-Veränderungen, die als Mikrosatelliten-Instabilität oder Mismatch-Reparatur-Mangel bezeichnet werden (Aktiv)
CINC280A2X02B Study to allow patients with cMET-dependent malignancies to continue capmatinib treatment as monotherapy or in combination treatment (Aktiv)
CLDK378A2407 study of ceritinib in patients with advanced solid tumors and hematological malignancies characterized by genetic abnormalities of ALK (Aktiv)
CatalYm CTL-002-001 First-in-Human Study of the GDF-15 Neutralizing Antibody CTL-002 in Patients With Advanced Cancer (GDFATHER) (Aktiv)
DLL3 A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3). (Aktiv)
EDO-S101-1001 Phase-I-Studie zur Untersuchung der Sicherheit, der pharmakokinetischen Profile sowie der Wirksamkeit von Tinostamustine, einem First-in-Class alkylierenden HDACi-Fusionsmolekül, bei rezidivierenden/refraktären hämatologischen Malignomen Eine Phase-1/2-Studie zur Untersuchung der Sicherheit, Pharmakokinetik und Wirksamkeit von EDO-S101, einem erstklassigen HDACi-Fusionsmolekül (Alkylating Histone Deacetylase Inhibition) bei Patienten mit fortgeschrittenen soliden Tumoren Untersuchung der Sicherheit, Phar (Aktiv)
F8394-201 A Phase 2 Master Protocol to assess the efficacy and safety of FORE8394, an inhibitor of BRAF class 1 and class 2 alterations, in participants with cancer harboring BRAF alterations (Aktiv)
ICT01-102 (EVICTION-2) A two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 in combination with low-dose subcutaneous interleukin-2 in patients with advanced solid tumors. (EVICTION-2) (Aktiv)
IGNYTE (RPL-001-16) Eine offene, multizentrische Phase-1/2-Studie mit RP1 als Einzelwirkstoff und in Kombination mit PD1-Blockade bei Patienten mit soliden Tumoren (Aktiv)
IMA 401-101 A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients With Recurrent and/or Refractory Solid Tumors. (Aktiv)
IMA402 (bispecific T cell engaging receptor molecule) A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors (Aktiv)
INFORM2-NivEnt (NCT-2017-0516) INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (Aktiv)
INSIGHT Phase I study to evaluate the feasibility and safety of IMP321 in solid tumors (Aktiv)
KontRASt-01 Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (Aktiv)
KontRASt-03 A Phase Ib/II, multicenter, open-label dose escalation and expansion platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation (Aktiv)
MCLA-128-CL01/MERUS A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)
MK-3475 Study of Pembrolizumab (MK-3475) in Children (Aktiv)
Olaparib / AstraZeneca A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with Solid Tumours (Aktiv)
Proto-R-Kinder Protonentherapie bei Kindern: Prospektive Erfassung von Effizienz und Nebenwirkungen bei klinischen Standarddosen (Aktiv)
REFIT-MSS (TRIO042) Eine offene Phase-II-Multikohorten-2-Stufen-Studie zur Bewertung der Wirksamkeit und Sicherheit von Regorafenib in Kombination mit Tislelizumab bei Patienten mit ausgewählten Mismatch-Reparatur profizienten/mikrosatellitenstabilen vorbehandelten soliden Krebsarten (Aktiv)
RadCav Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases - A Prospective Randomized Explorative Phase II Trial (Aktiv)
SATURNUS Hypofractionated stereotactic radiotherapy versus single fraction stereotactic radiotherapy to the resection cavity of brain metastases after surgical resection. (Aktiv)
SGNPDL1V-001 A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors (Aktiv)
SORATRAM Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)
STARVATION Short-term Starvation vs. Normal Diet before Chemotherapy of Solid Tumors (Aktiv)
STELLAR-002/XL092 A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors (Aktiv)
TAPISTRY Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial (Aktiv)